A comparative evaluation of pharmacokinetics of conventional and slow-release carbamazepine formulation in newly treated patients of epilepsy: A random evaluation

Journal of Association of Physicians of India

Volumn 46, Issue 2, 1998, Pages 185-188

  Nag, Devika ^a   Garg, R K ^a   Agarwal, A ^a  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE;

ADOLESCENT; ADULT; ARTICLE; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; EPILEPSY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; MALE; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTICONVULSANTS; CARBAMAZEPINE; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; EPILEPSY; EVALUATION STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PROBABILITY; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 0031987573     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Rall TW, Schleifer LS. Drug effective in the therapy of the epilepsies. In : Goodman, Gilman A et al. (Eds). The pharmacological basis of therapeutics, 8th ed. McGraw Hill : New York 1991; 1 : 436-62.
2. Mikati M. The newer antiepileptic drugs. Carbamazepine and valproic acid. Pediatr Ann 1991; 20 : 34-40.
3. Bialer M. Pharmacokinetic evaluation of sustained release formulations of antiepileptic drugs. Clinical Implications. Clin Pharmacokinet 1992; 22 : 11-21.
4. Ryan SW, Forsythe I, Harley R, et al. Slow release carbamazepine in treatment of poorly controlled seizures. Arch Dis Child 1990; 65 : 930-5.
5. Mckee PJW, Blacklaw J, Butler E, et al. Monotherapy with conventional and controlled release carbamazepine - A double blind, double dummy comparison in epileptic patients. Br J Clin Pharmacol 1991 ; 32 : 99-104.
6. Canger R, Altamura AC, Belvedere O, et al. Conventional vs controlled release carbamazepine. A multicentre, double blind, cross over study. Acta Neurol Scand 1990; 82 : 9-13.
7. Stefan H, Schafer H, Kuhnen C, et al. Clinical monitoring during carbamazepine slow-release, once daily monotherapy. Epilepsta 1988; 29 : 571-7.
8. McKee PJW, Blacklaw J, Butler E, et al. Conventional versus controlled release carbamazepine. Double blind, double dummy comparison in epileptic patients. Acta Neurol Scand 1990; 82 (Supp. 133) : 51.
9. Bonneton J, Iliadis A, Genton P, et al. Steady state pharmacokinetics of conventional versus controlled release carbamazepine in patients with epilepsy. Epilepsy Res 1993; 14 : 257-63.
10. Person LI, Ben Menachem E, Bengtsson E, et al. Differences in side effects between a conventional carbamazepine preparation and a slow-release preparation of carbamazepine. Epilepsy Res 1990; 6 : 134-40.
11. Eeg-Oloffoson O, Nilsson HL, Tonnby B, et al. Diurnal variation in carbamazepine and carbamazepine 10,11-epoxide in plasma and saliva in children with epilepsy, a comparison between conventional and slow-release formulations. J Child Neurol 1990; 5 : 159-65.
12. Van Der Meyden CH,. Bartel PR, Sommers DK, et al. Effect of acute doses of controlled release carbamazepine on clinical, psychomotor, electrophysiological and cognitive parameters of brain function. Epilepsia 1992; 33 : 335-42.
13. Larkin TG, McLellan A, Munday A, et al. A double blind comparison of conventional and controlled release carbamazepine in healthy subjects. Br J Clin Pharmacol 1989; 27: 313-22.